Fox Run Management L.L.C. Takes $86,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Fox Run Management L.L.C. purchased a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 33,504 shares of the company’s stock, valued at approximately $86,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Stephens Inc. AR bought a new stake in shares of ImmunityBio in the 4th quarter worth $26,000. Cibc World Markets Corp bought a new stake in ImmunityBio in the 4th quarter worth about $35,000. Maia Wealth LLC purchased a new stake in ImmunityBio in the 4th quarter valued at about $37,000. Schechter Investment Advisors LLC bought a new position in shares of ImmunityBio during the 4th quarter worth approximately $38,000. Finally, Captrust Financial Advisors purchased a new position in shares of ImmunityBio in the 3rd quarter worth approximately $41,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Trading Down 6.5 %

Shares of NASDAQ IBRX opened at $3.14 on Friday. The firm has a market cap of $2.68 billion, a price-to-earnings ratio of -3.41 and a beta of 0.82. The stock has a fifty day simple moving average of $3.13 and a two-hundred day simple moving average of $3.60. ImmunityBio, Inc. has a 1-year low of $2.28 and a 1-year high of $10.53.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.26) by $0.11. The firm had revenue of $7.55 million for the quarter, compared to the consensus estimate of $8.74 million. Analysts forecast that ImmunityBio, Inc. will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on IBRX. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of ImmunityBio in a research report on Thursday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research report on Thursday, March 13th. Finally, BTIG Research assumed coverage on shares of ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.19.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.